提高抗肝癌药物的肝脏浓度并降低心脏,血液浓度的实验研究

实验研究结果表明：阿霉素（ＡＤＭ）在采用推进法注射时，经肝血管或外周静脉途径二者的肝、心与血液浓度均无显著差别．如采用控速缓慢输注法，则经肝血管较经外周静脉在提高肝脏浓度方面具有显著效果，心脏内浓度也有一定程度降低。如在肝血管内输注时与血液净化联合应用，则更能提高上述要求。以上结果将为临床抗癌药介入治疗应用方法的开展提供依据和参考价值。     

黄芪注射液治疗心力衰竭46例临床观察

目的　探讨黄芪注射液对心力衰竭 (HF)的治疗效果。方法　选择 92例住院HF患者随机分为治疗组和对照组 ,对照组给予常规治疗 ,治疗组在常规治疗的基础上给予黄芪注射液 30ml加 5 %葡萄糖液 2 5 0ml,静滴 ,每日一次 ,共 2周。疗程结束后 ,观察心功能改善情况。结果　治疗组有效率 93.4 8% ,对照组有效率 71.74 % ,两组对比 ,差异显著 (P <0 .0 1)。结论　黄芪注射液对HF的治疗效果佳 ,副作用少 ,值得推广。     

灯盏花素合力源精纯溶栓酶治疗不稳定型心绞痛30例

目的 :观察灯盏花素、力源精纯溶栓酶治疗不稳定型心绞痛 (UAP)的临床疗效。方法 :将 6 0例 UAP患者随机分为治疗组和对照组各 30例。治疗组给予灯盏花素、力源精纯溶酶加常规抗心绞痛治疗 ;对照组仅给予常规抗心绞痛治疗。分别观察 2组治疗前后的心绞痛发作及硝酸甘油用量的变化 ,检测静息心电图和血液流变学指标。结果 :治疗组在缓解心绞痛总有效率 (93.33% )、改善异常心电图及血液流变学指标、降低硝酸甘油用量〔(0 .4 5± 0 .15 ) m g/ d〕等方面均显著优于对照组。结论 :灯盏花素联合力源精纯溶栓酶治疗 U AP疗效优于常规西药治疗。     

哮喘缓解期联用乌体林斯和黄芪注射液等穴位注射控制哮喘发作的临床观察

目的　观察哮喘缓解期联用乌体林斯、黄芪注射液、鱼腥草注射液穴位注射控制哮喘发作的疗效 ,探讨其作用机理。方法　哮喘缓解期患者 5 6例 ,随机分成两组。治疗组 3 2例采用相同穴位交替选择药物 ,隔日穴位注射治疗 ;对照组 2 4例予常规治疗。并观察两组疗效及治疗前后用力肺活量 (FVC) ,1秒钟用力呼气量 (FEV1)和肺活量 (VC)的变化。结果　两组总有效率为 96.87%和 79.17% ,治疗组优于对照组 ( χ2 =10 ,P <0 .0 1)。治疗组治疗前后肺功能明显改善 ,治疗前后比较VC分别为 ( 1.79± 0 .43 )L和 ( 2 .91± 0 .64 )L ,P <0 .0 5 ;FVC分别为 ( 1.64± 0 .46)L和 ( 2 .0 9±0 .62 )L ,P <0 .0 5 ;FEV1分别为 ( 0 .92± 0 .70 )L和 ( 1.3 5± 0 .3 5 )L ,P <0 .0 5。对照组治疗前后肺功能改善不明显 (P均<0 .0 5 )。治疗组明显优于对照组。结论　在哮喘缓解期联用乌体林斯、黄芪注射液、鱼腥草注射液穴位注射控制哮喘发作的临床疗效优于常规治疗     

参附注射液对肠缺血-再灌注大鼠肿瘤坏死因子α的影响

目的观察肿瘤坏死因子α(TNF-α)在大鼠肠缺血-再灌注损伤过程中的作用及参附注射液对TNF-α的影响,探讨参附注射液防治肠缺血-再灌注损伤机制。方法 SD大鼠随机分为肠缺血-再灌注组(IR组)、参附注射液预处理组(SF组)和假手术组(C组)。采用阻断肠系膜上动脉(SMA)的方法制造肠缺血-再灌注模型。分别测定各组动物血浆、肠组织TNF-α含量及血液动力学变化;光镜观察肠粘膜损伤情况。结果IR组再灌注后MAP下降,与C组和SF组比有显著性差异(P<0.01);SF组肠粘膜损伤程度减轻,与IR组比有显著性差异(P<0.01);SF组血浆及肠组织TNF-α水平降低,与IR组比有显著性差异(P<0.01)。结论参附注射液可明显防治大鼠肠缺血-再灌注导致的肠粘膜损伤,这种作用可能是通过抑制TNF-α的释放实现的。     

面部凹陷自体脂肪颗粒填充术的临床分析

目的探讨自体脂肪颗粒注射填充矫正面部凹陷畸形的临床效果。方法首先在患者脂肪丰厚的部位,注射器抽取脂肪颗粒,经清洗液反复冲洗后,将脂肪颗粒分点多层注入皮下。结果本组85例患者,55例注射1次,25例注射2次,5例注射3次。72例随访6~24个月,3例上下睑凹陷出现局部不平整,2例患者出现无菌性炎症,其余效果满意。结论面部凹陷畸形采用自体脂肪颗粒填充矫正,方法简单,安全有效。     

直肠黏膜高位柱状注射治疗直肠黏膜脱垂性便秘(附38例报告)

目的:探讨消痔灵注射在直肠内脱垂治疗中的临床应用及改良方法.方法:对38例直肠内脱垂患者行消痔灵直肠黏膜高位柱状注射治疗的临床资料进行分析总结.结果:术后随访1～24个月,治愈28例(占73.7%),好转7例(占18.4%),总有效率达92.1%.结论:消痔灵直肠黏膜高位柱状注射治疗直肠内脱垂具有操作简单、疗效可靠、并发症少、费用低廉的优点.     

醒脑静注射液治疗缺血性中风急性期随机对照试验的系统评价

目的 系统评价醒脑静注射液治疗缺血性中风急性期的疗效及安全性。方法 集醒脑静注射液治疗缺血性中风急性期随机对照试验文献，筛选合格研究，应用Jadad评分法进行质量评价，运用异质性检验、Meta-分析、漏斗图分析、敏感性分析等方法统计相关数据。结果 项研究符合纳入标准，Jadad评分所有研究得分均低于3分，属低质量文献。Meta-分析结果显示，总有效率比较的相对危险度（RR值）=1．04，99％的可信区间（CI值）为（0．88，1．23）。结论 前尚无充分证据证实醒脑静注射液治疗缺血性中风急性期的疗效及安全性。要进一步验证醒脑静注射液治疗缺血性中风急性期的疗效及安全性，尚需进行设计合理、执行严格、多中心大样本且随访时间足够的随机对照试验。     

The Effect of 50 Hz External Electrical Interference on Implanted Cardiac Pacemakers

The effects of injected 50 Hz alternating current on the function of cardiac pacemakers has been observed in 18 patients with implanted unipolar VVI units. Current, in the range 0-600 microA was applied via electrodes attached to the patients' upper body and feet and fed from a specially designed current injection unit at the bedside. Most implanted pacemakers reverted to interference mode in the current range 29-250 microA. At current levels just below the reversion current all units developed irregular and inappropriate pacing. This current level was pacemaker dependent and varied in the range 27-246 microA. The total reversion current depended on the location of the injecting electrodes and on the patients' posture. The sensitivity of the units to injected interference was increased by deep inspiration. Temporary pacing catheters fitted to an additional ten patients were used to monitor the interference voltage which would be sensed by an implanted unit. This voltage was similarly dependent on patient posture and on deep respiration. Current injection has proved to be a safe, controllable and reproducible method of testing the sensitivity of implanted pacemakers to 50 Hz external interference.     

Respiratory symptoms associated with the use of azodicarbonamide foaming agent in a plastics injection molding facility

Respiratory health variables were studied cross-sectionally in 227 employees of a plastics molding facility where numerous complaints had been apparently associated with the use of azodicarbonamide foaming agent in injection molding. Pre- and postshift respiratory status measures and azodicarbonamide concentrations were also obtained for 17 employees. Cross-sectional pulmonary function differences by injection molding status were not observed. Modest decrements in pulmonary function measures were observed between start and end of shift but with no dose-effect relationship. A strong association was observed for injection molding workers for eye/nose/throat irritation, cough, and wheezing. Additionally, wheezing, chest tightness, and symptoms of chronic bronchitis were strongly associated with work in injection molding during periods in which azodicarbonamide was in use. These results suggest respiratory symptom causation by some combination of azodicarbonamide itself, reaction products of azodicarbonamide formed during injection molding, or other unidentified agents uniquely associated with the process of injection molding with azodicarbonamide foaming agent.